Springer Nature
Browse
12933_2017_595_MOESM3_ESM.pdf (103.91 kB)

MOESM3 of Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin

Download (103.91 kB)
journal contribution
posted on 2017-09-13, 05:00 authored by Pia Pollack, Kristina Chadwick, David Smith, Martin Billger, Boaz Hirshberg, Nayyar Iqbal, David Boulton
Additional file 3. Saxagliptin and 5-hydroxy saxagliptin pharmacokinetic parameters for multiple ascending dose study in patients with T2DM.

Funding

AstraZeneca

History

Usage metrics

    Cardiovascular Diabetology

    Categories

    Keywords

    Diabetes mellitusPharmacologyHeart failureSaxagliptin

    Licence

    CC BY + CC0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC